Pharmacia & Upjohn's Xalatan will be available in late summer for second-line use in glaucoma.
Executive Summary
PHARMACIA & UPJOHN XALATAN OPHTHALMIC WILL BE AVAILABLE IN LATE SUMMER, the company said following June 5 FDA approval of Xalatan for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are either intolerant of or insufficiently responsive to another intraocular pressure-lowering product. The approval comes approximately one year after Pharmacia's submission of NDA 20-597 for latanoprost solution on June 14, 1995. Xalatan was designated a priority review by FDA.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth